
GAD: A Neglected Diagnosis With a New Investigational Treatment
Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.
CONFERENCE REPORTER
Daniel R. Karlin, MD, MA, sat down with Psychiatric Times at the 2024 American Psychiatric Association Annual Meeting to discuss both the epidemiological data on the unmet burden and underdiagnosis of generalized anxiety disorder (GAD) shared here at the meeting, as well as the potential of upcoming treatment lysergide d-tartrate program (MM-120).
The US Food and Drug Administration has granted breakthrough designation to
Dr Karlin is the chief medical officer of MindMed and a fellow of the APA.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.